The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit HR may represent an effective strategy to enhance their activity in HR-proficient tumors. Using a bioinformati...

A novel bioresponsive controlled-release biosensor using Au nanocages capped with an aptamer-based molecular gate was reported for the first time. The use of aptamers as caps has proven to be a suitable method for the preparation of "bio-gated" delivery systems that can be selectively opened in the presence of target biomolecules.